The Latest Breakthroughs in Immunotherapy for GU Cancers

AUAUniversity

English - December 27, 2023 06:30 - 37 minutes - 33.9 MB - ★★★★★ - 32 ratings
Courses Education Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Germline Testing and Novel Approaches to Targeting Genetic Mutations in Prostate Cancer

Next Episode: Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:
The Latest Breakthroughs in Immunotherapy for GU Cancers

CME Available: https://auau.auanet.org/node/39543
Release Date: December, 2023
Expiration Date: December, 2024

LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Identify the newest immunotherapy drugs approved for prostate, bladder, and kidney cancer, including immune checkpoint inhibitors and other novel immunotherapies.
2. Discuss the clinical evidence supporting the use of these immunotherapy drugs in prostate, bladder, and kidney cancer, including data from pivotal clinical trials, response rates, and survival outcomes.
3. Evaluate the safety profile and potential immune-related adverse events associated with the newest immunotherapy drugs in GU cancers.

ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lantheus Medical Imaging
Merck & Co., Inc.